# Comparative Analysis of Amelogenin-Derived Peptides LRAP and SP on Osteogenic Differentiation of Human Dental Pulp and Bone Marrow-Derived Stem Cells

**Authors:** Carmela Del Giudice, Giuliana La Rosa, Carmen Vito, Roberto Tiribuzi, Gianrico Spagnuolo, Ciro Menale, Carlo Rengo, Antonino Fiorino

PMC · DOI: 10.3390/dj14020094 · 2026-02-06

## TL;DR

This study compares two amelogenin-derived peptides on their ability to promote bone-like cell development in dental and bone marrow stem cells.

## Contribution

The study reveals distinct signaling mechanisms of LRAP and SP in promoting osteogenic differentiation in different stem cell types.

## Key findings

- LRAP and SP increased ALP activity and mineral deposition in both hDPSCs and hBMSCs at 10 ng/mL.
- LRAP significantly upregulated osteogenic and odontogenic gene expression in hDPSCs.
- LRAP induced nuclear β-catenin translocation in hDPSCs, while SP caused membrane-associated accumulation in hBMSCs.

## Abstract

Background/Objectives: This study aimed to compare the biological effects of two amelogenin-derived peptides—the leucine-rich amelogenin peptide (LRAP) and a synthetic peptide (SP)—on human dental pulp stem cells (hDPSCs) and human bone marrow–derived mesenchymal stem cells (hBMSCs). The investigation focused on cell viability, osteogenic differentiation, mineralization, gene expression, and β-catenin expression. Methods: hDPSCs and hBMSCs were cultured in osteogenic medium and treated with LRAP and SP at 1, 5, 10, 50, and 100 ng/mL. Cytotoxicity was assessed by MTT assay, while osteogenic differentiation was evaluated by alkaline phosphatase (ALP) activity and Alizarin Red S staining. Gene expression of RUNX2, COL1A1, OCN, MEPE, and DMP1 was quantified by qPCR. β-catenin localization was analyzed by immunofluorescence. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test (p < 0.05). Results: Both peptides exhibited good biocompatibility with hBMSCs, while high concentrations (≥50 ng/mL) reduced hDPSC viability. In both cell types, LRAP and SP increased ALP activity and mineral deposition in a concentration-dependent manner, with the greatest effects at 10 ng/mL. LRAP significantly upregulated osteogenic (RUNX2, COL1A1, OCN) and odontogenic (MEPE, DMP1) gene expression in hDPSCs. Immunofluorescence revealed nuclear β-catenin translocation in hDPSCs and membrane-associated accumulation in hBMSCs, indicating activation of canonical and non-canonical pathways, respectively. Conclusions: LRAP and SP promote osteogenic differentiation through distinct cell-type-specific signaling mechanisms, highlighting their potential as biomimetic agents for mineralized tissue regeneration.

## Linked entities

- **Genes:** RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632], MEPE (matrix extracellular phosphoglycoprotein) [NCBI Gene 56955], DMP1 (dentin matrix acidic phosphoprotein 1) [NCBI Gene 1758]
- **Proteins:** ctnnb1.S (catenin beta 1 S homeolog)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], EEF2 (eukaryotic translation elongation factor 2) [NCBI Gene 1938] {aka EEF-2, EF-2, EF2, SCA26}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, SP5 (Sp5 transcription factor) [NCBI Gene 389058], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, DMP1 (dentin matrix acidic phosphoprotein 1) [NCBI Gene 1758] {aka ARHP, ARHR, DMP-1}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, CTNNB1 (catenin beta 1) [NCBI Gene 539003], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, DSPP (dentin sialophosphoprotein) [NCBI Gene 1834] {aka DFNA39, DGI1, DMP3, DPP, DSP}, ACRV1 (acrosomal vesicle protein 1) [NCBI Gene 56] {aka D11S4365, SP-10, SPACA2}, LSM10 (LSM10, U7 small nuclear RNA associated) [NCBI Gene 84967] {aka MST074, MSTP074}, ERAP2 (endoplasmic reticulum aminopeptidase 2) [NCBI Gene 64167] {aka L-RAP, LRAP}, FEZ1 (fasciculation and elongation protein zeta 1) [NCBI Gene 9638] {aka UNC-76}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, Tff2 (trefoil factor 2 (spasmolytic protein 1)) [NCBI Gene 21785] {aka SP, mSP}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, alp (alopecia, recessive) [NCBI Gene 11691], ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, FLOT1 (flotillin 1) [NCBI Gene 10211], MEPE (matrix extracellular phosphoglycoprotein) [NCBI Gene 56955] {aka OF45}
- **Diseases:** Cytotoxicity (MESH:D064420), skeletal defects (MESH:C567306), postoperative pain (MESH:D010149), inflammatory (MESH:D007249), injury to (MESH:D014947), CSDs (MESH:D016638)
- **Chemicals:** Alexa Fluor  488 (MESH:C000711379), beta-glycerophosphate (MESH:C031463), dexamethasone (MESH:D003907), MTT (MESH:C070243), PBS (-), Alizarin Red (MESH:C010078), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), DMSO (MESH:D004121), DAPI (MESH:C007293), calcium (MESH:D002118), Alizarin Red S (MESH:C004468), paraformaldehyde (MESH:C003043), CO2 (MESH:D002245), Triton  X-100 (MESH:D017830), Formazan (MESH:D005562), alpha-MEM (MESH:C420642), acetic acid (MESH:D019342), isopropanol (MESH:D019840), ascorbic acid (MESH:D001205), TRIzol (MESH:C411644)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** G9422-50G
- **Cell lines:** ST2 — Mus musculus (Mouse), Stromal cell line (CVCL_2205), MC3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0D74)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939566/full.md

---
Source: https://tomesphere.com/paper/PMC12939566